Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 124 full-time employees. The company went IPO on 2020-12-04. The company is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. The company has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Dr. Omid Farokhzad 2017 'den beri şirketle birlikte olan Seer Inc 'in Chairman of the Board 'ıdır.
SEER hissesinin fiyat performansı nasıl?
SEER 'in mevcut fiyatı $1.93 'dir, son işlem günde 0% azalmış etti.
Seer Inc için ana iş temaları veya sektörler nelerdir?
Seer Inc Life Sciences Tools & Services endüstrisine ait ve sektör Health Care 'dir
Seer Inc 'in piyasa değerlemesi nedir?
Seer Inc 'in mevcut piyasa değerlemesi $108.8M 'dir
Seer Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Seer Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir